REGN earnings analysis
What we found in REGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Regeneron's Q1 2026 results revealed revenues of $3.605 billion, a significant increase from $3.029 billion in Q1 2025, but diluted EPS of $6.75 fell short of the consensus estimate of $8.38 primarily due to an R&D charge. The company remains optimistic about product sales, particularly for Dupixent and EYLEA, while reaffirming its full-year guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Q1 2026 revenue increased to $3.605 billion from $3.029 billion in Q1 2025, representing a 19% year-over-year growth.
- Dupixent Sales Surge
- The sales of Dupixent continue to drive revenues significantly, with considerable growth reported in recent months.
- EYLEA HD® Performance
- Sales for EYLEA HD® showed strong performance, contributing positively to the overall revenue stream.
- R&D Investments
- The company is actively investing in research and development, significant enough to impact net income.
- Operating Cash Flow
- Operating cash flow for Q1 2026 was reported at $800 million.
- Strong Market Position
- Regeneron maintains substantial market share in critical therapeutic areas, bolstered by recent approvals.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- IPR&D Charge Impact
- Regeneron incurred an IPR&D charge affecting net income, which fell to $727.2 million from $808.7 million year-over-year.
- Falling GAAP Net Income
- Net income decreased to $727.2 million in Q1 2026 from $808.7 million in Q1 2025, indicating pressure on profitability.
- EYLEA® Sales Decline
- There is potential risk related to declining EYLEA® sales as competition in the ophthalmology market intensifies.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $6.75
What they said about what is next.
Regeneron reaffirmed its guidance for 2026, indicating stability in revenue expectations despite current challenges.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing REGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever